Physician profile
Michael A Scannon
NPI 1396734851
$217,710.62
in general payments reported to CMS, 2019-2025
26 companies · $16K in 2025
The $16K reported for 2025 was more than what 91% of Procedural Dermatology providers received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52K · 2020: $24K · 2021: $8,523 · 2022: $40K · 2023: $45K · 2024: $32K · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $79K · Travel and Lodging: $9,565 · Food and Beverage: $4,366 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $79,475.00 |
| Travel and Lodging | $9,565.29 |
| Food and Beverage | $4,365.70 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $196,036.67 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Celgene Corporation | $9,321.52 | 2019 | |
| Amgen INC. | $6,920.34 | 2019-2025 | Otezla |
| Novartis Pharmaceuticals Corporation | $3,887.16 | 2019-2025 | |
| Dermavant Sciences, INC. | $184.41 | 2023 | Vtama |
| Janssen Biotech, INC. | $161.89 | 2021-2025 | Tremfya |
| Revance Therapeutics, INC. | $141.96 | 2025 | Daxi |
| E.R. Squibb & Sons, L.L.C. | $134.94 | 2023 | Opdivo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $125.08 | 2019-2025 | Siliq, Cabtreo, Jublia |
| Ucb, INC. | $103.96 | 2019-2025 | Bimzelx |
| Organon LLC | $101.43 | 2025 | Vtama, Nexplanon |
| Sun Pharmaceutical Industries INC. | $95.02 | 2019-2025 | |
| Pfizer INC. | $85.04 | 2024-2025 | |
| Smith+Nephew, INC. | $65.90 | 2024-2025 | Grafix Pl, Collagenase Santyl |
| Arcutis Biotherapeutics, INC. | $62.59 | 2024-2025 | Zoryve |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $52.17 | 2019-2025 | Libtayo, Dupixent |
| Biofrontera INC. | $45.03 | 2025 | Ameluz |
| Lilly USA, LLC | $40.34 | 2025 | Ebglyss, Taltz |
| Genzyme Corporation | $30.44 | 2025 | |
| Sandoz INC. | $23.91 | 2019 | |
| Surgenex LLC | $17.61 | 2025 | Renograft, Pellograft, Surgraft |
| Galderma Laboratories, L.P. | $16.54 | 2025 | |
| Genentech USA, INC. | $14.47 | 2019 | |
| Leo Pharma INC. | $14.37 | 2021 | |
| Kerecis Limited | $14.01 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Strata Skin Sciences, INC. | $13.82 | 2024 | Xtrac |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Scannon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.